Evidence map›Paper›PMID 31669367›Full record

ArticleInfection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases2020

Correlates of hepatitis C viral clustering among people who inject drugs in Baltimore.

Jada Hackman, Oluwaseun Falade-Nwulia, Eshan U Patel, Shruti H Mehta, Gregory D Kirk, Jacquie Astemborski, Stuart C Ray, David L Thomas, Oliver Laeyendecker

Abstract read
In one paragraph

Article in Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Identification of Genetically Related HCV Infections Among Self-Described Injecting Partnerships.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2022
    Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Jada HackmanDivision of Intramural Research, National Institutes of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States of America.
Oluwaseun Falade-NwuliaDepartment of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States of America.
Eshan U PatelDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, United States of America.
Shruti H MehtaDepartment of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States of America.
Gregory D KirkDepartment of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States of America; Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, United States of America.
Jacquie AstemborskiDepartment of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States of America.
Stuart C RayDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, United States of America.
David L ThomasDepartment of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States of America; Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, United States of America.
Oliver LaeyendeckerDivision of Intramural Research, National Institutes of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States of America; Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States of America; Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, United States of America. Electronic address: olaeyen1@jhmi.edu.

Funding

LC: HIV Prevention Trials Network - Laboratory Support for the SARS-CoV-2 Seroprevalence Study (CoVPN 5002)UM1AI068613 · NIAID · JOHNS HOPKINS UNIVERSITY · PI SUSAN H ESHLEMAN, Mark A Marzinke · 2011 to 2026
$100.2M
Vaccine Response and Immunotherapeutics SWGP30AI094189 · NIAID · JOHNS HOPKINS UNIVERSITY · PI Anna Palmer Durbin · 2012 to 2026
$67.0M
The AIDS Linked to the Intravenous Experience (ALIVE) StudyU01DA036297 · NIDA · JOHNS HOPKINS UNIVERSITY · PI Gregory D Kirk, Shruti H Mehta · 2014 to 2026
$28.9M
International Studies of the Acquired Immune Deficiency Syndrome (AIDS)ZIAAI000361 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI REDD, ANDREW · 2009 to 2025
$15.8M
INCIDENCE OF HIV INFECTIONS IN A COHORT OF IV DRUG USERSR01DA012568 · NIDA · JOHNS HOPKINS UNIVERSITY · PI MEHTA, SHRUTI H · 1999 to 2017
$15.5M
Johns Hopkins HIV Epidemiology and Prevention Sciences Training ProgramT32AI102623 · NIAID · JOHNS HOPKINS UNIVERSITY · PI Shruti H Mehta · 2013 to 2026
$5.3M
The impact of social networks on hepatitis C transmission and care access in people who inject drugsK23DA041294 · NIDA · JOHNS HOPKINS UNIVERSITY · PI FALADE-NWULIA, OLUWASEUN · 2016 to 2020
$924k
Intramural NIH HHS Z99 AI999999NIAID NIH HHS P30 AI094189NIAID NIH HHS T32 AI102623NIAID NIH HHS UM1 AI068613NIDA NIH HHS K23 DA041294NIDA NIH HHS R01 DA012568NIDA NIH HHS U01 DA036297
6 · The paper itself

Abstract

This study examines correlates of hepatitis C virus (HCV) genetic clustering among community-recruited people who inject drugs enrolled in the AIDS Linked to the IntraVenous Experience cohort in Baltimore between 1988 and 1989. HCV RNA was extracted and the core/envelope-1 region was sequenced. Clusters were identified from maximum likelihood trees with 1000 bootstrap replicates using a 70% aLRT and a 4% genetic-distance threshold in Cluster Picker. Overall, 46% of participants were in a cluster, including 122 genotype-1a and 36 genotype-1b clusters with an average of 2-3 genetically linked HCV infections. The largest cluster consists of 9 participants. In univariable analysis, black race (PR = 1.66 [95% CI: 1.12-2.45]), age <35 years (PR = 1.18 [95% CI: 1.02-1.37]), and injection drug use of cocaine alone (PR = 1.30 [95% CI: 1.02-1.65]) were significantly associated with being in a cluster. Conversely, a history of medication-associated treatment (MAT) was negatively associated with being in a cluster (PR = 0.82 [95% CI: 0.71-0.95]). In multivariable analysis, black race (APR = 1.62 [95% CI: 1.11-2.38]) remained independently associated being in a cluster while MAT (APR = 0.85 [95% CI: 0.74-0.99]) remained negatively associated with clustering. Our findings suggest strong locally-propagated transmission networks during the early epidemic that was driven by younger PWID. In light of the current opioid epidemic in the US, these findings suggest an urgent need for preventive interventions to mitigate the growth of large HCV transmission networks.

Indexed as

AdultBaltimoreCluster AnalysisFemaleGenotypeHepacivirusHepatitis CHumansMalePhylogenySubstance Abuse, Intravenous1CEHepatitis C virusInjection drug useMolecular epidemiologyPhylogeneticPWID

Identifiers

PMID31669367
PMCPMC7460273

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.